Use of cabergoline and related ergoline derivatives for controlling intraocular pressure
US5705510A · kind A · utility
14Cited by
9References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 25, 1995 |
| Grant date | Jan 6, 1998 |
| Priority date | — |
| Expiry date | Oct 25, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The use of certain dopaminergic compounds for controlling elevations of intraocular pressure is disclosed. The compounds are ergoline derivatives. The most preferred compound is cabergoline. The compounds have been found to produce a significant reduction of intraocular pressure.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.